About Millendo Therapeutics
Millendo Therapeutics is a Healthcare company based in Ann Arbor (United States) founded in 2012. Immune-mediated targeted therapies for cancer are developed. Millendo Therapeutics has raised $102.77 million across 5 funding rounds from investors including University of Michigan, Frazier Healthcare Partners and NEA. The company has 30 employees. Millendo Therapeutics has completed 1 acquisition, including Alizé Pharma. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Endocrine disorders. Its legal entity is ATTEROCOR INC. Its competitors include BeiGene, Moderna and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Millendo Therapeutics was founded in 2012 in Ann Arbor, United States, within the biotechnology sector. Focus is placed on immune-mediated targeted therapies for cancer. The product pipeline is composed of TPST-1120, a PPARα antagonist used in hepatocellular carcinoma, cholangiocarcinoma, and renal cell carcinoma; TPST-1495, applied to multiple solid tumors; and a TREX-1 inhibitor. Operations center on advancing these candidates through clinical development.
- Headquarters Ann Arbor, United States
- Employees 30
- SectorsHealthcare
- Website millendo.com
- Social X
- Legal Name Atterocor Inc
- Total Equity Funding$102.77M (USD)
in 5 rounds
- Latest Funding Round$62M (USD), Series B
Jan 2016
- InvestorsUniversity of Michigan
& 9 more
- Employee Count30
- Investments & Acquisitions
Funding Insights of Millendo Therapeutics
Millendo Therapeutics has successfully raised a total of $102.77M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $62 million completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $102.77M
- Total Rounds 5
- Last Round Series B — $62M
- First Round $250,000
(Apr 2012)
- Investors Count 10
All 5 funding rounds of Millendo Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2016 | $62M | Series B | – | New Enterprise Associates | |
| Feb 2013 | $8.52M | Private Equity Round | – | – | – |
| Feb 2013 | $16M | Series A | – | 5AM Ventures, Frazier Healthcare Partners | – |
| Aug 2012 | $16M | Series A | – | – | |
| Apr 2012 | $250,000 | Seed | – | – | – |
10 investors in total: 10 institutional.
Investors in Millendo Therapeutics
Millendo Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include University of Michigan, Frazier Healthcare Partners and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Venture capital is directed toward healthcare companies by Longwood Fund. | longwoodfund.com | Boston, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Private markets investment management with strategies in equity, credit, and secondary investments. | adamsstreetpartners.com | |||
Early stage life sciences sectors focused VC firm investing in the US | altitudelsv.com | Kirkland, United States | ||
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
Corporate-backed venture capital firm focused on the healthcare sector | roche.com/venturefund.htm | |||
Operates as a fund of funds in the venture capital sector. | 2002 | renvcf.com | Ann Arbor, United States | |
Graduation and postgraduate courses are offered in diverse academic streams. | 1817 | umich.edu | United States |
Investor details for Millendo Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Millendo Therapeutics
18 people are tracked at Millendo Therapeutics (5 in leadership, 11 in board & advisors, 2 in team); the tracked headcount is 30.
| Name | Role | Group |
|---|---|---|
Nicholas Maestas | VP, Strategy & Finance | Leadership |
Darrin Bomba | VP, Clinical Operations | Leadership |
Stephen Brady | President & CEO | Leadership |
John "Robbie" Starbody | Associate Director, Accounting & Finance | Leadership |
Soyoung Han | Sr. Director, Clinical Operations | Leadership |
Drew M. Pardoll | Advisor | Board & advisors |
Geoff Nichol | Board Member | Board & advisors |
Benjamin F. Cravatt | Advisor | Board & advisors |
Mike Raab | Chairman, Board of Directors | Board & advisors |
Christine Pellizzari | Board Member | Board & advisors |
Peppi Prasit | Advisor | Board & advisors |
Toni K. Choueiri | Advisor | Board & advisors |
Jason J. Luke | Advisor | Board & advisors |
Ronit Simantov | Board Member | Board & advisors |
Russell Vance | Advisor | Board & advisors |
Raymond N. DuBois | Advisor | Board & advisors |
Justin Trojanowski, CPA | Corporate Controller | Team |
Dara Burdette | Consultant | Team |
Complete people profiles for Millendo Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Millendo Therapeutics
Millendo Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Alizé Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Develop drugs, proteins and peptides for the treatment of metabolic and rare diseases | alz-pharma.com | Ecully, France | 2007 | Dec 2017 | •••• |
Complete acquisition details for Millendo Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Millendo Therapeutics
4 dated milestones of Millendo Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Millendo Therapeutics is founded.
- Funding First funding round of $250K.
- Funding Latest funding round, Series B, of $62.0M.
- Acquisition Acquires Alizé Pharma.
Competitors of Millendo Therapeutics
Millendo Therapeutics has 3 listed competitors in our database, 2 of them funded. They include BeiGene, Moderna and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Millendo Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Millendo Therapeutics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Millendo Therapeutics
Complete news archive for Millendo Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Millendo Therapeutics
Millendo Therapeutics was founded in 2012.
Millendo Therapeutics is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Millendo Therapeutics is a funded company, having raised a total of $102.77M across 5 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Apr 2012.
Millendo Therapeutics has 30 employees.
Millendo Therapeutics was founded in 2012 in Ann Arbor, United States, within the biotechnology sector. Focus is placed on immune-mediated targeted therapies for cancer. The product pipeline is composed of TPST-1120, a PPARα antagonist used in hepatocellular carcinoma, cholangiocarcinoma, and renal cell carcinoma; TPST-1495, applied to multiple solid tumors; and a TREX-1 inhibitor. Operations center on advancing these candidates through clinical development.
Millendo Therapeutics has made 1 acquisition, including Alizé Pharma.
Millendo Therapeutics has 10 investors. Key investors include University of Michigan, Frazier Healthcare Partners, NEA, 5AM Ventures, and Renaissance Venture Capital Fund.
Millendo Therapeutics operates through Atterocor Inc.